NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Avammune Therapeutics

Avammune Therapeutics

Private
Philadelphia, PennsylvaniaHealthcare & Life Scienceshttps://www.avammune.com/

Last Round

Series A

May 7, 2025

Total Funding Raised

$24M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Avammune Therapeutics is a biopharmaceutical company developing a pipeline of small-molecule drugs designed to modulate the innate immune system for treating cancer and autoimmune disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

immunotherapydrug discoverybiotechnologypreclinical developmentbiopharmacomputational chemistrybioinformaticstherapeutic candidatessmall-molecule therapeuticsradioligand therapeuticsdrug pipelineai-driven drug discoveryin silico drug designbiotech startuptarget identification

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Avammune Therapeutics Comparables

Compare Avammune Therapeutics with similar companies based on industry and business-model similarity.

Avammune Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Avammune Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 7, 2025
Series AMay 7, 2024
AngelJul 15, 2022
SeedJul 9, 2019

Avammune Therapeutics Investors

Notable investors and investment history

Avammune Therapeutics investors
InvestorRounds
The Chennai AngelsAngel
Shastra VCSeries A
1CrowdSeries A
Capital 2BSeries A
IvyCap VenturesSeries A
Kotak Alternate Asset ManagersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 13, 2026

    Grew 21% QoQ, from 14 to 17 employees.

  • Apr 26, 2026

    Grew 45% QoQ from 11 to 16 employees.

Avammune Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Avammune Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Avammune Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersPhiladelphia, Pennsylvania
Employee Range19
Year Founded2019
Last FundingMay 7, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.